AMP v Myriad The Supreme Court Gives a Win to Personalized Medicine
作者： Roger D. Klein
DOI: 10.1016/J.JMOLDX.2013.09.002
关键词:
摘要: … law that are sufficient to ensure that the patent is “significantly more than a patent on the natural law … up’ the use of such tools and thereby ‘inhibit future innovation premised on them.’” …
unirioja.es
jmdjournal.org参考文章(8)
仁三 藤野, アメリカ最高裁研究会, アメリカ法判例研究(9) I 代謝物を利用した治療方法の特許適格性-Mayo Collaborative Services v. Prometheus Laboratories Inc., 132 S. Ct. 1289 (2012) 比較法学. ,vol. 46, pp. 224- 235 ,(2012)
涼子 井関, 遺伝子特許に関する米国連邦最高裁判決の意義[Ass'n for Molecular Pathology (AMP) v. Myriad Genetics, Inc., 133 S. Ct. 2107, 186 L. Ed. 2d 124 (2013)] ジュリスト = Monthly jurist. pp. 72- 78 ,(2013)
Roger D Klein, Gene patents and genetic testing in the United States. Nature Biotechnology. ,vol. 25, pp. 989- 990 ,(2007) , 10.1038/NBT0907-989
Robert Cook-Deegan, John M Conley, James P Evans, Daniel Vorhaus, The next controversy in genetic testing: clinical data as trade secrets? European Journal of Human Genetics. ,vol. 21, pp. 585- 588 ,(2013) , 10.1038/EJHG.2012.217
Timothy Caulfield, Robert M Cook-Deegan, F Scott Kieff, John P Walsh, Evidence and anecdotes: an analysis of human gene patenting controversies Nature Biotechnology. ,vol. 24, pp. 1091- 1094 ,(2006) , 10.1038/NBT0906-1091
R D Klein, Legal developments and practical implications of gene patenting on targeted drug discovery and development. Clinical Pharmacology & Therapeutics. ,vol. 87, pp. 633- 635 ,(2010) , 10.1038/CLPT.2010.47
Debra G. B. Leonard, Medical Practice and Gene Patents Academic Medicine. ,vol. 77, pp. 1388- 1391 ,(2002) , 10.1097/00001888-200212001-00010
Mildred K. Cho, Samantha Illangasekare, Meredith A. Weaver, Debra G.B. Leonard, Jon F. Merz, Effects of Patents and Licenses on the Provision of Clinical Genetic Testing Services The Journal of Molecular Diagnostics. ,vol. 5, pp. 3- 8 ,(2003) , 10.1016/S1525-1578(10)60444-8